New Delhi, January 16
The Resident Doctors’ Association (RDA) of the Ram Manohar Lohia Hospital here on Saturday requested the medical superintendent to vaccinate them with Oxford COVID-19 vacc
NEW DELHI: The Resident Doctors Association (RDA) of the Ram Manohar Lohia Hospital here on Saturday requested the medical superintendent to vaccinate them with Oxford Covid-19 vaccine Covishield.
In a letter to the medical superintendent, the association said the resident doctors were a bit apprehensive about Covaxin and might not participate in the immunisation drive in large numbers thus defeating the purpose of the exercise which began in the country on Saturday. We have come to know that the Covid-19 vaccination drive is being conducted by the hospital today. Covaxin manufactured by Bharat Biotech is being preferred in our hospital over Covishield manufactured by Serum Institute.
Final preparations underway for nationwide rollout of COVID-19 vaccination drive today ANI | Updated: Jan 16, 2021 10:04 IST
New Delhi [India], January 16 (ANI): Final preparations are underway for the nationwide rollout of the COVID-19 vaccination drive, which will be launched by Prime Minister Narendra Modi today.
Billed as the world s largest vaccination program, covering the entire length and breadth of the country, the drive aims to first inoculate millions of its healthcare and frontline workers and reach an estimated 3 crore people by the end of its first phase.
A total of 3,006 session sites across all States and Union Territories will be virtually connected during the launch. Around 100 beneficiaries will be vaccinated at each session site on the inaugural day.
The doctors' apprehension is based on the fact that 'Covaxin' lacks complete trial data on the public domain, while 'Covishield' has successfully completed all stages of the trial.
"The residents are a bit apprehensive about the lack of complete trial in case of Covaxin and might not participate in huge numbers thus defeating the purpose of vaccination. We request you to vaccinate us with Covishield which has completed all stages of trial before its roll-out," the letter stated.